Form 8-K - Current report:
SEC Accession No. 0001213900-25-044894
Filing Date
2025-05-16
Accepted
2025-05-16 16:15:08
Documents
13
Period of Report
2025-05-13
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0242374-8k_hoth.htm   iXBRL 8-K 24842
  Complete submission text file 0001213900-25-044894.txt   200053

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE hoth-20250513.xsd EX-101.SCH 3038
3 XBRL LABEL FILE hoth-20250513_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE hoth-20250513_pre.xml EX-101.PRE 22374
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0242374-8k_hoth_htm.xml XML 3805
Mailing Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036
Business Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38803 | Film No.: 25959422
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)